Benchmark Rates Unicycive Therapeutics (UNCY) buy
Benchmark has reiterated its buy rating on Unicycive Therapeutics with a price target of $13, a 169.78% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Benchmark rated Unicycive Therapeutics, Inc. ($UNCY) "buy" with a $13 price target on July 1, 2026.
Since the rating, $UNCY is up 2.8% after 1 week, down 5.1% after 1 month and down 36.4% to date (from the $5.28 close on Jul 1, 2026).
UNCY
Unicycive Therapeutics, Inc.
Key Points
- Benchmark reiterated its buy rating on Unicycive Therapeutics, Inc. with a target of $13, while the stock trades at $4.82.
- Benchmark's $13 price target implies 169.78% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- The stock has seen a 52-week low of $3.71 and a high of $8.74, indicating it remains significantly below its potential.
- Analysts have varying targets for Unicycive, with Noble Capital Markets setting a high target of $50.
Get $UNCY trade alerts by text
We text you when insiders, Congress or big funds trade $UNCY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Unicycive Therapeutics, Inc. alert may contain errors. Disclosures
Benchmark Maintains Positive Outlook
On July 1, 2026, Benchmark reiterated its buy rating on Unicycive Therapeutics, Inc. (NasdaqCM: UNCY) with a price target of $13. The stock was priced at $4.82 at the time of the announcement, showing a substantial gap between the current price and the analyst's target.
Benchmark vs. the S&P 500
Hypothetical returns from Benchmark's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Benchmark's latest rating aligns with a generally positive outlook from other analysts. On the same day, Noble Capital Markets maintained a buy rating with a target of $50, while HC Wainwright & Co. also reaffirmed its buy rating with a target of $15. This suggests that several firms see potential in Unicycive, despite its current trading price.
Stock Performance Insights
Unicycive's shares have fluctuated within a 52-week range from $3.71 to $8.74. As of the last close at $4.82, the stock is well below its high, which may present an opportunity for investors looking at the firm's future potential. The stock also trades below its 50-day moving average of $5.22, indicating it might be undervalued in the current market.
$UNCY price target
Unicycive Therapeutics, Inc. daily closes and this analyst's $13 target. Not advice.
Recent Earnings
Unicycive Therapeutics is expected to report its next earnings on November 12, 2026. The company has been working on therapies for kidney diseases, which are crucial given the growing need for effective treatments in this area. Its current focus includes oxylanthanum carbonate and UNI-494, both targeting significant health issues.
What Unicycive Therapeutics, Inc. Does
Unicycive Therapeutics, based in Mountain View, California, is a clinical-stage biotechnology firm focused on developing treatments for kidney diseases. Its innovative therapies aim to address critical health challenges, which is why the recent analyst ratings are particularly relevant for understanding its market potential.
What’s Next for Unicycive
Investors should keep an eye on Unicycive's upcoming earnings report in November and any further analyst updates. The recent reiteration of buy ratings suggests confidence in the company's future, despite current share price challenges. Remember that the 13F filings can provide insight into institutional holdings, reflecting past positions that may not indicate current trends.
Related Filing Alerts
Source: Benchmark's rating change on $UNCY (Jul 1, 2026). Written by software, not financial advice. How we make alerts